NCT07402577 Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
| NCT ID | NCT07402577 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Roswell Park Cancer Institute |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2026-03-30 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study generates information on the feasibility and acceptability of a 3-month ecological momentary assessment (EMA) protocol to assess chronic pain and opioid use in adolescent and young adult (AYA) sarcoma survivors.
Eligibility Criteria
Inclusion Criteria: * All genders between the ages of 12-24 (inclusive) at sarcoma diagnosis. * Any age \< 70 at the time of study enrollment. * No evidence of disease and/or enrolled in survivorship care. * Clinically meaningful pain related to disease or its treatments at baseline (defined as 3 or greater on a 0-10 Numerical Rating Scale). * Willing to attend the baseline appointment in person. * Access to internet-capable smartphone. * Access to internet on an occasional basis. * Willing and able to complete Ecological Momentary Assessments (EMAs) on internet-capable smartphone for a 3-month period after enrollment. * Ability to understand and provide informed consent/assent. Exclusion Criteria: * \* Currently receiving active cancer-directed therapy. * Unable to read or fluently speak English. * Determined by clinical staff to have preexisting or cancer-associated cognitive impairment that could interfere with study participation. * Acutely suicidal (e.g. intent or plan) or, with unstable medical or psychiatric condition verified by licensed study staff. * Characteristics related to inability to complete the study protocol.
Contact & Investigator
Andrew Rogers
PRINCIPAL INVESTIGATOR
Roswell Park
Frequently Asked Questions
Who can join the NCT07402577 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 70 Years, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07402577 currently recruiting?
Yes, NCT07402577 is actively recruiting participants. Contact the research team at Andrew.Rogers@roswellpark.org for enrollment information.
Where is the NCT07402577 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT07402577 clinical trial?
NCT07402577 is sponsored by Roswell Park Cancer Institute. The principal investigator is Andrew Rogers at Roswell Park. The trial plans to enroll 40 participants.